Compare EVLV & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVLV | NNNN |
|---|---|---|
| Founded | 2013 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.5B |
| IPO Year | N/A | 2025 |
| Metric | EVLV | NNNN |
|---|---|---|
| Price | $6.52 | $32.92 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $9.13 | N/A |
| AVG Volume (30 Days) | ★ 2.4M | 37.0K |
| Earning Date | 02-27-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.06 |
| Revenue | ★ $136,501,000.00 | $6,920,153.00 |
| Revenue This Year | $41.16 | N/A |
| Revenue Next Year | $14.71 | N/A |
| P/E Ratio | ★ N/A | $487.83 |
| Revenue Growth | ★ 43.16 | N/A |
| 52 Week Low | $2.64 | $5.18 |
| 52 Week High | $8.91 | $55.65 |
| Indicator | EVLV | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 46.08 | 45.85 |
| Support Level | $7.02 | $28.61 |
| Resistance Level | $7.29 | $33.96 |
| Average True Range (ATR) | 0.31 | 4.30 |
| MACD | -0.07 | -0.80 |
| Stochastic Oscillator | 35.89 | 8.27 |
Evolv Technologies Holdings Inc offers an AI-based touchless security screening. Its touchless security screening systems use artificial intelligence software, cloud services, and sensors to reliably detect dangerous weapons while ignoring harmless items like cell phones, laptops, and keys. It offers products for purchase under a multi-year security-as-a-service subscription pricing model that delivers ongoing value to customers, generates predictable revenue, and creates expansion and upsell opportunities. The firm operates in a single segment that develops, manufactures, markets, and sells security screening products and specific services. Its products are used in different industries such as casinos, industrial workplaces, schools, and ticketed venues.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.